Señales en vivo de NPTX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (13 jun 2023 @ 12:01):

Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary synthetic cannabinoid derivatives platform...

Stats
Volumen de hoy	10 000.00
Volumen promedio	13 596.00
Capitalización de mercado	28 143.00
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.00750
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2022-06-06	Petkanas Dean	Sell	10 000	Common Stock
2022-06-07	Petkanas Dean	Sell	50 000	Common Stock
2022-06-08	Petkanas Dean	Sell	21 836	Common Stock
2022-06-09	Petkanas Dean	Sell	238 164	Common Stock
2022-06-13	Petkanas Dean	Sell	300 000	Common Stock

INSIDER POWER
-100.00
Last 56 transactions
Buy: 20 518 991 \| Sell: 5 700 000

Volumen Correlación

Largo: -0.12 (neutral)

Corto: 0.00 (neutral)

Signal:(47.122) Neutral

Neuropathix, Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Neuropathix, Inc. Correlación - Moneda/Commodity

0.00
( neutral )

Neuropathix, Inc. Finanzas

Annual	2021
Ingresos:	$183 477
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.0480

FY	2021
Ingresos:	$183 477
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.0480

FY	2020
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.0600

FY	2019
Ingresos:	$126 027
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.0500

Financial Reports:

No articles found.

Neuropathix, Inc.

Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary synthetic cannabinoid derivatives platform. It engages in the research and development of chemical entities, such as KLS-13019, KLS-13023, and KLS-13022, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of chemotherapy induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. The company was formerly known as Kannalife, Inc. and changed its name to Neuropathix, Inc. in November 2020. Neuropathix, Inc. was founded in 2010 and is based in Doylestown, Pennsylvania.